Market: Euronext Growth Paris
ISIN Code: FR0014003XT0
Mnemo Code: ALNFL
Sector: Biotechnology
PEA-PME: Yes
JP Morgan Healthcare Conference: January 16 & 17, 2024
BIOMED Event (Investor Conference):January 30, 2024
2023 annual results: March 29, 2024
Annual General Meeting (Montpellier): May 30, 2024
2024 half-year results: September 27, 2024
February 2, 2023
A rewarding preclinical success (french)
October 12, 2023
Visibility Q4 24, strategic review on NFL-101 (french)
September 26, 2023
PRECESTO positive, 2023 newsflow sacrificed on CESTO2 (french)
June 23, 2023
Development plan validated by EMA (french)
April 26, 2023
Financial visibility Q3 24, newsflow key element (french)
February 1st, 2023
Extended visibility thanks to AK’s success (french)
January 23, 2023
A busy year in 2023 for clinical development (french)
March 29, 2022
An acceleration of OPEX in 2022 (french)
September 17, 2021
CESTO2 now an international trial
September 6, 2021
An innovative approach to treat addiction